{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:22:27Z","timestamp":1780060947874,"version":"3.54.0"},"reference-count":31,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100015217","name":"Veloxis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015217","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Transplantation"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Envarsus XR\u00ae (LCPT), a once daily dosage formulation of tacrolimus, is an FDA\u2010approved medication in adult renal transplant recipients (RTRs). There are limited data on its pharmacokinetics (PK) in adolescent RTRs. We report here the PK profile of LCPT in adolescent RTRs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The dose of LCPT was determined using a dose conversion ratio targeting 0.7 relative to the total daily immediate\u2010release tacrolimus (IR\u2010Tac) dose. On day 7 after converting to LCPT, patients had an abbreviated PK assessment with sampling at: 0\u2009h (pre\u2010dose), 8\u2010, and 12\u2010h post\u2010dose. The PK data analysis was performed using Bayesian estimators. Our results were compared to those of published adult PK data for LCPT and pediatric PK data for IR\u2010Tac and extended release tacrolimus (ER\u2010Tac) formulation (Advagraf).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>PK data from three adolescent patients on LCPT were evaluated. The mean (\u00b1SD) area under the time\u2013concentration curve (AUC) was 240 (\u00b120.22) h*ng\/mL. The mean <jats:italic>T<\/jats:italic><jats:sub>max<\/jats:sub> was 9.01\u2009\u00b1\u20092.12\u00a0h, and the % fluctuation was 77.71\u2009\u00b1\u20093.96%. The AUC, <jats:italic>T<\/jats:italic><jats:sub>max<\/jats:sub>, and % fluctuation were similar to reported results in adult patients taking LCPT. The AUC was higher and the <jats:italic>T<\/jats:italic><jats:sub>max<\/jats:sub> was longer than what has been reported in pediatric patients taking IR\u2010Tac and ER\u2010Tac. In addition, the LCPT group showed a lower % fluctuation than patients receiving ER\u2010Tac.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The PK evaluation of LCPT in adolescent RTRs showed similar results to adults. Adolescents taking LCPT had a higher AUC, a more attenuated <jats:italic>T<\/jats:italic><jats:sub>max<\/jats:sub>, and a lower fluctuation than that seen with ER\u2010Tac in pediatrics.<\/jats:p><\/jats:sec>","DOI":"10.1111\/petr.14480","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T02:40:03Z","timestamp":1675392003000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Envarsus <scp>XR<\/scp>\u00ae pharmacokinetics in adolescents post\u2010kidney transplantation \u2013 A pilot study"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1313-0926","authenticated-orcid":false,"given":"Rim","family":"ElChaki","sequence":"first","affiliation":[{"name":"Division of Pediatric Nephrology, Department of Pediatrics University of California Los Angeles  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9973-7349","authenticated-orcid":false,"given":"Robert","family":"Ettenger","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, Department of Pediatrics University of California Los Angeles  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Services Ronald Reagan UCLA Medical Center  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medicine Statistics Core University of California Los Angeles  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Gales","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, Department of Pediatrics University of California Los Angeles  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6588-0315","authenticated-orcid":false,"given":"Rachana","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, Department of Pediatrics University of California Los Angeles  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6070-4793","authenticated-orcid":false,"given":"Meghan","family":"Pearl","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, Department of Pediatrics University of California Los Angeles  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12579"},{"key":"e_1_2_8_3_1","first-page":"1465","article-title":"Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients","volume":"4","author":"Webster A","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e318198d092"},{"key":"e_1_2_8_5_1","first-page":"96","article-title":"Formulation development forum: controlled agglomeration for poorly soluble drugs","volume":"35","author":"Arnum PV","year":"2011","journal-title":"Pharm Technol"},{"key":"e_1_2_8_6_1","article-title":"Improved Bioavailability of MELTDOSE Once\u2010Daily Formulation of Tacrolimus (LCP\u2010Tacro) with Controlled Agglomeration Allows for Consistent Absorption over 24 Hrs: A Scintigraphic and Pharmacokinetic Evaluation [abstract number: B1034]","volume":"13","author":"GA NV","year":"2013","journal-title":"Am J Transplant"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0349-2"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182962cc1"},{"key":"e_1_2_8_9_1","first-page":"355","article-title":"A phase 2 randomized study of the pharmacokinetics, safety and efficacy of LCP\u2010Tacro tablets once\u2010a\u2010day vs Prograf capsules twice\u2010a\u2010day in de novo kidney transplants","volume":"11","author":"Alloway R","year":"2011","journal-title":"Am J Transplant"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12035"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/12.8.1668"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-013-2564-y"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13935"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0533-5"},{"key":"e_1_2_8_15_1","first-page":"1","article-title":"Using the Student's t\u2010test with extremely small sample sizes","volume":"18","author":"Winter JCF","year":"2013","journal-title":"Pract Assess Res Eval"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12955"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12581"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.10.024"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics2030291"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181b2a0e0"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2010.01299.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2005.00356.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31823411d7"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2008.03.090"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1074584"},{"key":"e_1_2_8_26_1","unstructured":"ENVARSUS XR [package insert].Veloxis Pharmaceuticals Inc;2018."},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318200e991"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13495"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2014.38"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1591"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.07.018"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008030287"}],"container-title":["Pediatric Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/petr.14480","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/petr.14480","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/petr.14480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T08:58:57Z","timestamp":1724835537000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/petr.14480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/petr.14480"],"URL":"https:\/\/doi.org\/10.1111\/petr.14480","archive":["Portico"],"relation":{},"ISSN":["1397-3142","1399-3046"],"issn-type":[{"value":"1397-3142","type":"print"},{"value":"1399-3046","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]},"assertion":[{"value":"2022-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e14480"}}